Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) almost screens out as though it was being acquired. How many times does non-buyout news drive gains north of 70%? In emerging pharma and biotech, it happens more than in other sectors. The news this morning is that Merck KGaA has signed a global agreement with Threshold to co-develop and commercialize Phase 3 Hypoxia-Targeted drug TH-302, which is Threshold’s small molecule hypoxia-targeted drug.
As far as what this translates to, Threshold will receive $25 million as an upfront payment and it is set to receive further milestone payments and royalty payments upon certain targets being achieved. With a market cap of only $63 million and with a recent cash balance of only about $25 million ahead of the news, this is driving home for speculative traders.
After closing at $1.29, the stock’s pre-market surge is a whopping 77% at $2.28. Threshold has a 52-week trading range of $1.20 to $3.34. Threshold has no product revenues as of yet. We have also already seen over 300,000 shares trade hands in the pre-market and the average daily volume is only 136,000 shares.
JON C. OGG
ALERT: Take This Retirement Quiz Now (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
